FBXL22, a circadian-regulated immune biomarker with pan-cancer prognostic value and therapeutic potential in prostate cancer
Abstract F-box and leucine-rich repeat protein 22 (FBXL22) has been implicated in breast and prostate cancer types; however, comprehensive pan-cancer…
